4/22/2021 0 Comments Bastien Piano Website
Please take the time to read over our consent form with family members andor your doctor to see if this study is the best fit for you.As many women receive these during their prime reproductive years, the information from PIANO will be valuable in guiding therapy of women with CD or UC who wish to have children while receiving this therapy for their illness.If you are interested in enrolling please call 415-885-3734 or email email protected.We ask that you complete a questionnaire at each trimester of your pregnancy, at the end of your pregnancy, 4, 9, and 12 months post-delivery, and once a year up to the age of 15 years of age.
Depending on the results of your newborns blood work at delivery we also ask for blood work form your newborn at 3 and 6 months post-delivery. This is part of the standard of care to ensure that your infant had an appropriate response to vaccines. If you choose to take part in this part of the study, a blood sample will be taken from your child by placing a needle in hisher vein. You can choose not to give your infants blood sample for this test and still take part in this study. The development of T and B cells is very important for keeping your child healthy and preventing injections. If you choose to participate in this part of the study, a blood collection kit will be sent to you prior to the blood draw. This blood draw can be done at a local commercial lab or pediatricians office. The blood sample will be taken from your child by placing a needle in their vein. Approximately 2 mL or of a teaspoon of blood will be obtained. So far results have been reassuring, but the more data we have the better we can determine this. A stool collection kit will be sent to you if you choose to take part in this optional study. ![]() We are also able to discover if your newborn has early-life microbial-derived products that promote immune dysfunction just by your infants stool samples. She completed a residency in internal medicine at Mount Sinai Medical Center in New York, a fellowship in gastroenterology at the University of California, San Francisco (UCSF) and a fellowship in inflammatory bowel disease (IBD) at the Mayo Clinic in Rochester, Minnesota. Dr. Mahadevan currently serves as Professor of Medicine at UCSF, Clinical Services Chief for Gastroenterology, and Co-Director of the UCSF Center for Colitis and Crohns Disease and Director of the IBD Fellowship. She is a Fellow of the American College of Gastroenterology and serves on the Educational Affairs Committee and as a member of the Advanced IBD Fellow Curriculum Committee. She is currently Chair of the Crohns Colitis Foundation Clinical Research Grants committee and a member of their National Scientific Advisory Committee and Taskforce on Women in IBD. Dr. Mahadevan has published original articles, abstracts, editorials, and invited reviews in such peer-reviewed journals as Gastroenterology, American Journal of Gastroenterology, Inflammatory Bowel Diseases, and Gut along with several book chapters. She has a particular interest in pregnancy and fertility in IBD, as well as in clinical trials of experimental therapy for both ulcerative colitis and Crohns disease. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO), clinical trials in biologic therapy for IBD, and the impact of nutritional interventions in the management of IBD.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |